boehringer glp-1 use tripled among non-diabetics, reaching $5.8B in 2022 GLP-1 Competitive Environment - Citrini

This can affect potency and effectiveness

Major pharmaceutical companies have embarked on historic capital build-outs (totaling tens of billions) to enlarge production of GLP-1 APIs and formulations ( [5] ) ( [23] )

Because of these findings, regulatory bodies like the FDA in the United States and the MHRA in the UK issued warnings

Who manufactures Trulicity

These results were attributed not just to improved glycemic control, but to anti-inflammatory effects on arterial walls, reduced plaque formation, and enhanced endothelial function

This code indicates that a patient is currently using insulin as part of their ongoing diabetes management